Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities.
about
Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature ReviewCT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive ReviewRadioembolization of hepatic lesions from a radiobiology and dosimetric perspectivePrognostication and response assessment in liver and pancreatic tumors: The new imagingTreatment of primary liver tumors with Yttrium-90 microspheres (TheraSphere) in high risk patients: analysis of survival and toxicities.Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver.Radioembolization of yttrium-90 microspheres for hepatic malignancy.Transarterial therapies for hepatocellular carcinoma.The role of (18)F-FDG positron emission tomography in the follow-up of liver tumors treated with (90)Yttrium radioembolization.Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio.Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneityRadioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma.Treatment of hepatocellular carcinoma by means of radiopharmaceuticals.Factors associated with increased incidence of severe toxicities following yttrium-90 resin microspheres in the treatment of hepatic malignanciesRadioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors.A review of 3D image-based dosimetry, technical considerations and emerging perspectives in (90)Y microsphere therapy.Treatment of large and advanced hepatocellular carcinoma.Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical reviewAdministered activity and outcomes of glass versus resin (90)Y microsphere radioembolization in patients with colorectal liver metastases.Y-90 microshperes in the treatment of unresectable hepatocellular carcinoma.A first report of radioembolization for hepatic metastases from ocular melanoma.Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension.Liver transplantation after radioembolization in a patient with unresectable HCC.Serious hepatic complications of selective internal radiation therapy with yttrium-90 microsphere radioembolization for unresectable liver tumors.Other non-surgical treatments for liver cancer.Hepatic radioembolization complicated by fulminant hepatic failureComparison of the Adverse Event Profile of TheraSphere® with SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review.Incidence and risk factors of early arterial blood flow stasis during first radioembolization of primary and secondary liver malignancy using resin microspheres: an initial single-center analysis.Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer.Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report.[Intra-arterial treatment of liver metastases from colorectal carcinoma].Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience.Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation.Safety of repeated yttrium-90 radioembolization.Planning transarterial radioembolization of colorectal liver metastases with Yttrium 90 microspheres: evaluation of a sequential diagnostic approach using radiologic and nuclear medicine imaging techniques.Liver transarterial embolizations in metastatic neuroendocrine tumors.Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres.Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres.Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization.Effectiveness of repeat angiographic assessment in patients designated for radioembolization using yttrium-90 microspheres with initial extrahepatic accumulation of technitium-99m macroaggregated albumin: a single center's experience.
P2860
Q26743603-F01A3380-0BEF-4D45-A283-F7AFEFF8FCFAQ26770014-49C1EF58-FF38-41BA-9A25-4174FA9D43FBQ26998661-B3F24785-468E-47F8-A1EF-F54892C382F2Q27021568-2B3B8F72-5A36-4AED-AEF6-BF522DAC4379Q30447735-C077CD42-73B1-45ED-AA60-7A13C023BF11Q34563356-F58CB905-B91D-429C-BFBB-3C4F49BBB171Q34563515-1BEA91B7-FF40-4B04-8523-0C2BFAF21086Q34628257-F7A25AD7-F8C2-4C3C-8E5F-4A41B082E9D8Q35656582-5A38B635-3E05-42DA-97FB-FF98BC26114AQ35738820-ED614408-3F15-4072-90B3-5E2A95FB39B1Q35985132-2A5842C6-7044-47D0-B89E-33DF753F6441Q36062588-DE343BBD-E0BD-4F34-9F69-EEF39E7D0418Q36201164-0D307657-A155-4AD7-A707-DFA7C2CBB555Q36656612-531EA6D8-815B-4492-9D4E-27C48BA84AFAQ36728823-DD4872EA-EA70-4DA0-A6CE-DE19C3BDAAC4Q36899620-6A5608A8-8577-439B-BF17-4D8AB260D3BEQ37072529-EE22B2D5-0ED2-4145-B2C7-696DCF8AD113Q37113543-C001AB4E-DB73-487C-B966-8F206A3B0B0CQ37131705-D5F52749-644B-4D59-A537-3AADBDDEF3CAQ37243546-591C0353-809B-4692-A50B-62CC44976F4FQ37393973-ABB30505-C2CA-407F-8192-9BA9C5FF3B65Q37623505-F0ACD144-1FE0-4AAB-A977-777C7EA2477CQ37625817-7116FEE0-5AB0-4965-B8A7-A6AC5F9583EDQ38241076-6FCE970D-2D9F-472F-9D5A-CD1E6341CBF5Q38685463-4479A05D-17B5-4A3F-9B37-14CDAA5A724DQ38705100-E35CB163-2BD3-42BA-8432-8D4C3F677B19Q38936579-C8ABE63A-9B66-4D13-94C1-B43F5AC10CFCQ40330206-ECC345C7-D666-404F-B7AA-14CFBD2CB872Q41344992-C30ECD3D-191C-413F-938C-B73932D12AB4Q42015157-7748B488-57DF-43DA-9809-87F1E0CA9BC4Q42125152-9A244372-C5BB-4BB0-9D02-7DE129381E7CQ42370609-8D2E2278-23B5-4DFB-AADC-05B850AF5282Q42601023-0F31D4EE-C40E-4807-A076-B480D5781BD6Q44200845-9B95BAF4-D685-436C-816A-C5361394708BQ46823324-039D2C1C-DF1C-4104-8EDE-106B9771FAD1Q47869784-82634692-C184-4F86-B970-C002B6807BFCQ47953062-1169A600-8E14-40D3-A3C5-5A3A427C17CFQ51097558-F712FFB3-B246-4A3E-8509-F317EF6375AFQ51192472-74FE9D78-8E69-42CB-9436-103D408FF3B0Q51540607-B9D7917C-F16D-4B69-B3EE-E38E0DB9D118
P2860
Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Treatment of unresectable hepa ...... ociated with liver toxicities.
@en
Treatment of unresectable hepa ...... ociated with liver toxicities.
@nl
type
label
Treatment of unresectable hepa ...... ociated with liver toxicities.
@en
Treatment of unresectable hepa ...... ociated with liver toxicities.
@nl
prefLabel
Treatment of unresectable hepa ...... ociated with liver toxicities.
@en
Treatment of unresectable hepa ...... ociated with liver toxicities.
@nl
P2093
P1476
Treatment of unresectable hepa ...... ociated with liver toxicities.
@en
P2093
James E Goin
Janet E Dancey
Jean Francois H Geschwind
Kathleen Goin
Kenneth Thurston
Mark Van Buskirk
Michael C Soulen
P304
P356
10.1097/01.RVI.00001142592.89564.F9
P433
P577
2005-02-01T00:00:00Z